Authors: Anna E. Vilgelm, Nabil Saleh, Rebecca Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau-Chiann Chen, C. Andrew Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al-Rohil, Ensar Halilovic, Rondi M. Kauffmann, Mark Kelley, Gregory D. Ayers, Ann Richmond
Published: 2019-08-14
DOI: 10.1126/scitranslmed.aav7171
Source: Full article
CDK4/6 inhibition becomes effective in preclinical models of melanoma when combined with MDM2 antagonism.